| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| DEUCRAVACITINIB (has an active metabolite)
| DEUCRAVACITINIB | IMMUNOSUPPRESSANTS | ORAL | Cmax 105.7 NANOMOLAR Tmax 2.5 HOUR F 99 PERCENT VD 140 LITER PPB 86 PERCENT Cl 2.4 LITER / HOUR HT 10 HOUR SOLUBILITY PH DEPENDENT DECREASES WITH INCREASING PH | TYROSINE KINASE 2 (TYK2) PDB 6NZP (CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH COMPOUND-11) LIGAND CODE = LB7 (link to the list of PDB complexes) Download experimental 3D coordinates of LB7 with added hydrogens | tyrosine kinase 2 (TYK2) UNIPROT P29597 more at DrugCentral | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| M DEUCRAVACITINIB (is an active metabolite)
| DEUCRAVACITINIB | IMMUNOSUPPRESSANTS | - | Cmax 12.1 NANOMOLAR | TYROSINE KINASE 2 (TYK2) | tyrosine kinase 2 (TYK2) UNIPROT P29597 more at DrugCentral | EMA | |||
